Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 1, 2010, Pages 17-25

  Numoto, Kunihiko ^a   Yoshida, Aki ^a   Sugihara, Shinsuke ^b   Kunisada, Toshiyuki ^a   Morimoto, Yuki ^a   Yoneda, Yasushi ^a   Fujita, Yasuko ^a   Nishida, Keiichiro ^a   Ouchida, Mamoru ^a   Ozaki, Toshifumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

5 aza 2 deoxycytidine; DNA methylation; RASSF1A; Soft tissue sarcoma; Synovial sarcoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; SARCOMA CELL; SYNOVIAL SARCOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, SYNOVIAL; TIME FACTORS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71449101475     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0632-2     Document Type: Article

References (40)

1. A Agathanggelou WN Cooper F Latif 2005 Role of the Ras-association domain family 1 tumor suppressor gene in human cancers Cancer Res 65 3497 3508 10.1158/0008-5472.CAN-04-4088 15867337 (Pubitemid 40616319)
2. DG Burbee E Forgacs S Zochbauer-Muller, et al. 2001 Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression J Natl Cancer Inst 93 691 699 10.1093/jnci/93.9.691 11333291
3. J Clark PJ Rocques AJ Crew, et al. 1994 Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma Nat Genet 7 502 508 10.1038/ng0894-502 7951320 (Pubitemid 24308337)
4. R Dammann C Li JH Yoon, et al. 2000 Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat Genet 25 315 319 10.1038/77083 10888881 (Pubitemid 30437320)
5. DR de Bruijn SV Allander AH van Dijk, et al. 2006 The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation Cancer Res 66 9474 9482 10.1158/0008-5472.CAN-05-3726 17018603 (Pubitemid 44623645)
6. DR de Bruijn JP Nap AG van Kessel 2007 The (epi)genetics of human synovial sarcoma Genes Chromosomes Cancer 46 107 117 10.1002/gcc.20399 17117414 (Pubitemid 44913376)
7. H Donninger MD Vos GJ Clark 2007 The RASSF1A tumor suppressor J Cell Sci 120 3163 3172 10.1242/jcs.010389 17878233 (Pubitemid 350018407)
8. NR dos Santos DR de Bruijn AG van Kessel 2001 Molecular mechanisms underlying human synovial sarcoma development Genes Chromosomes Cancer 30 1 14 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G 11107170
9. FC Eilber MF Brennan FR Eilber, et al. 2007 Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma Ann Surg 246 105 113 10.1097/01.sla.0000262787.88639.2b 17592298 (Pubitemid 47012214)
10. A Ferrari A Gronchi M Casanova, et al. 2004 Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution Cancer 101 627 634 10.1002/cncr.20386 15274077 (Pubitemid 38970615)
11. J Goffin E Eisenhauer 2002 DNA methyltransferase inhibitors-state of the art Ann Oncol 13 1699 1716 10.1093/annonc/mdf314 12419742 (Pubitemid 35439450)
12. JG Herman SB Baylin 2003 Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042 2054 10.1056/NEJMra023075 14627790 (Pubitemid 37448928)
13. T Ito M Ouchida S Ito, et al. 2004 SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex Lab Invest 84 1484 1490 10.1038/labinvest.3700174 15467731 (Pubitemid 39482165)
14. T Ito M Ouchida Y Morimoto, et al. 2005 Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo Cancer Lett 224 311 319 10.1016/j.canlet.2004.10.030 15914281 (Pubitemid 40725851)
15. H Kantarjian Y Oki G Garcia-Manero, et al. 2007 Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 52 57 10.1182/blood-2006-05-021162 16882708 (Pubitemid 46053042)
16. Kawaguchi KI, Oda Y, Saito T et al (2005) DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19:106-114
17. A Kawai N Naito A Yoshida, et al. 2004 Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1 Cancer Lett 204 105 113 10.1016/j.canlet.2003.09.031 14744540 (Pubitemid 38117199)
18. P Lazcoz J Munoz M Nistal, et al. 2006 Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma BMC Cancer 6 254 10.1186/1471-2407-6-254 17064406 (Pubitemid 44712383)
19. M Lemaire GG Chabot NJ Raynal, et al. 2008 Importance of dose-schedule of 5-aza-2′-deoxycytidine for epigenetic therapy of cancer BMC Cancer 8 128 10.1186/1471-2407-8-128 18454857 (Pubitemid 351715874)
20. JJ Lewis CR Antonescu DH Leung, et al. 2000 Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity J Clin Oncol 18 2087 2094 10811674
21. Lorente A, Mueller W, Urdangarin E et al (2008) RASSF1A, BLU, NORE1A, PTEN and MGMT Expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 19:279-292
22. JM Lubieniecka DR de Bruijn L Su, et al. 2008 Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma Cancer Res 68 4303 4310 10.1158/0008-5472.CAN-08-0092 18519690
23. ME Lusher JC Lindsey F Latif, et al. 2002 Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development Cancer Res 62 5906 5911 12384556
24. RL Momparler 2005 Epigenetic therapy of cancer with 5-aza-2′- deoxycytidine (decitabine) Semin Oncol 32 443 451 10.1053/j.seminoncol.2005.07. 008 16210084 (Pubitemid 41396420)
25. S Nagayama T Katagiri T Tsunoda, et al. 2002 Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray Cancer Res 62 5859 5866 12384549 (Pubitemid 35204746)
26. N Naito A Kawai M Ouchida, et al. 2000 A reverse transcriptase-polymerase chain reaction assay in the diagnosis of soft tissue sarcomas Cancer 89 1992 1998 10.1002/1097-0142(20001101)89:9<1992::AID-CNCR16>3.0.CO;2-R 11064357 (Pubitemid 30804753)
27. Y Nakagawa K Numoto A Yoshida, et al. 2006 Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization J Cancer Res Clin Oncol 132 444 450 10.1007/s00432-006-0089-5 16557383 (Pubitemid 43747392)
28. HJ Oh KK Lee SJ Song, et al. 2006 Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis Cancer Res 66 2562 2569 10.1158/0008-5472.CAN-05-2951 16510573
29. L Pazzaglia MS Benassi P Ragazzini, et al. 2006 Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity Histol Histopathol 21 187 195 16329043
30. GP Pfeifer R Dammann 2005 Methylation of the tumor suppressor gene RASSF1A in human tumors Biochemistry (Mosc) 70 576 583 10.1007/s10541-005-0151-y (Pubitemid 40920802)
31. B Ruter P Wijermans R Claus R Kunzmann M Lubbert 2007 Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7 Blood 110 1080 1082 10.1182/blood-2007-03-080630 17644749 author reply 1083 (Pubitemid 47267457)
32. T Saito Y Oda K Kawaguchi, et al. 2004 E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma Oncogene 23 8629 8638 10.1038/sj.onc.1207960 15467754 (Pubitemid 39576470)
33. K Schmelz N Sattler M Wagner, et al. 2005 Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation- dependent and -independent mechanisms Leukemia 19 103 111 15510208
34. C Seidel F Bartel M Rastetter, et al. 2005 Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma Int J Cancer 114 442 447 10.1002/ijc.20707 15551306 (Pubitemid 40279967)
35. L Shivakumar J Minna T Sakamaki R Pestell MA White 2002 The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation Mol Cell Biol 22 4309 4318 10.1128/MCB.22.12.4309-4318.2002 12024041 (Pubitemid 34556598)
36. H Sonobe Y Manabe M Furihata, et al. 1992 Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II Lab Invest 67 498 505 1331610
37. S Tommasi R Dammann Z Zhang, et al. 2005 Tumor susceptibility of Rassf1a knockout mice Cancer Res 65 92 98 15665283
38. L van der Weyden KK Tachibana MA Gonzalez, et al. 2005 The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis Mol Cell Biol 25 8356 8367 10.1128/MCB.25.18.8356-8367.2005 16135822 (Pubitemid 41263023)
39. CJ van Groeningen A Leyva AM O'Brien HE Gall HM Pinedo 1986 Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients Cancer Res 46 4831 4836 2425959
40. B Zhang T Huang K Liu J Chen G Wang 2007 Effects of 5-Aza-CdR on cell proliferation of breast cancer cell line MDA-MB-435S and expression of maspin gene J Huazhong Univ Sci Technolog Med Sci 27 543 546 10.1007/s11596-007-0517-z 18060631